Nabriva Therapeutics’ Pleuromutilin Antibiotic BC-3781 Shows Therapeutic Potential for Skin and Lung Infections

14-Sep-2010 - Austria

Nabriva Therapeutics announced that a series of studies will be presented at the 50th Interscience Conference on Antimicrobial Agents and chemotherapy (ICAAC) in Boston. The studies show that the Company’s novel pleuromutilin antibiotic BC-3781 can be used orally as well as intravenously for the treatment of skin and lung infections caused by MRSA and other bacteria. BC-3781 exhibits attractive safety, tolerance and pharmacokinetics and is currently in Phase II for acute bacterial skin and skin structure infections (ABSSSI).

Dr. Rodger Novak, Nabriva’s COO, will present an oral summary of the Company’s posters on pleuromutilin BC-3781 at the Session on “Novel antimicrobial agents”. He will be presenting data demonstrating BC-3781’s anti-microbial spectrum and it’s efficacy in non-clinical studies of both skin (ABSSSI) and lung infections, including community-acquired bacterial pneumonia (CABP), as well as data showing the pharmacokinetics of the molecule in clinical Phase I studies when administered intravenously.

Additionally, Nabriva’s CMO, Dr. William Prince will be presenting the latest research results on “Safety, Tolerance and Pharmacokinetics of Single and Repeat Doses of Oral BC-3781, a Novel Antimicrobial”. Study results showed that oral BC-3781 was well tolerated in patients and plasma concentration levels of BC-3781 indicated a therapeutic potential for the treatment of bacterial lung and skin infections.

https://www.bionity.com/en/news/122782/nabriva-therapeutics-pleuromutilin-antibiotic-bc-3781-shows-therapeutic-potential-for-skin-and-lung-infections.html